Faricimab

Evidence, trials and EU product information for faricimab.

Drug profile

Generic name
faricimab
Commercial names
Vabysmo
Class
Bispecific monoclonal antibody
Mechanism
Targets VEGF-A and angiopoietin-2.
Indications
Adults with neovascular (wet) AMD, visual impairment due to diabetic macular oedema, or visual impairment due to macular oedema secondary to retinal vein occlusion.
EU regulatory status
Authorised in the European Union. Current indications and prescribing details: EMA product information.

Current product information · EMA ↗ · 20 Sept 2026

Regulatory & safety updates

Timeline

  1. Faricimab: start with the current EU product information

References